Last reviewed · How we verify
IV ceftriaxone
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins.
Ceftriaxone is a third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. Used for Bacterial infections including meningitis, pneumonia, gonorrhea, and other serious gram-positive and gram-negative infections, Surgical prophylaxis.
At a glance
| Generic name | IV ceftriaxone |
|---|---|
| Also known as | ceftriaxone, Ceftriaxone |
| Sponsor | RESnTEC, Institute of Research |
| Drug class | Third-generation cephalosporin |
| Target | Penicillin-binding proteins (PBPs) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Ceftriaxone works by disrupting the cross-linking of peptidoglycan in the bacterial cell wall, leading to cell wall instability and bacterial death. It has broad-spectrum activity against gram-positive and gram-negative bacteria, with enhanced activity against gram-negative organisms compared to earlier cephalosporin generations. The IV formulation allows for rapid systemic distribution and is commonly used for serious infections requiring parenteral therapy.
Approved indications
- Bacterial infections including meningitis, pneumonia, gonorrhea, and other serious gram-positive and gram-negative infections
- Surgical prophylaxis
Common side effects
- Diarrhea
- Rash
- Phlebitis at injection site
- Nausea
- Hypersensitivity reactions
Key clinical trials
- Study of Ceftriaxone and Benzathine Penicillin G During Pregnancy
- Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial (PHASE2)
- Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease (EARLY_PHASE1)
- Gram-Negative Bloodstream Infection Oral Antibiotic Therapy Trial (NA)
- Oral Switch During Treatment of Left-sided Endocarditis Due to Multi-susceptible Streptococcus (PHASE3)
- Ceftriaxone for Post-Treatment Lyme Disease (PHASE1, PHASE2)
- Improvement of PPROM Management With Prophylactic Antimicrobial Therapy (iPROMPT) (PHASE4)
- Comparison Between Two Durations of Antibiotherapy for Non-surgically-treated Diabetic Foot Osteomyelitis (CHRONOS-2) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |